11/07/2013 18:45:00

U.K. Recalls Drugs Made in India

LONDON--In another sign of possible manufacturing problems in India's pharmaceutical industry, the U.K.'s medicines regulator said it was recalling 16 drugs made by Wockhardt Ltd. (532300.BY) after finding "manufacturing deficiencies" at one of the company's factories in India.

The Medicines and Healthcare products Regulatory Agency, or MHRA, called it a "precautionary recall," as there is no evidence that the medicines are defective. The agency said it is recalling the drugs from pharmacies and wholesalers but isn't asking patients to return their Wockhardt medicines.

"There is no evidence of a patient safety risk. ...however, the MHRA has to act in the interest of public health as poor manufacturing standards cannot be allowed to continue," the agency said.

The recalled drugs, manufactured in the central Indian city of Waluj, include treatments for infections, hypertension, diabetes, epilepsy and other diseases. The MHRA said the plant suffered from "poor cleaning practices" and defective ventilation systems. The agency inspection also found evidence of "forged documents relating to staff training records."

In an emailed statement, Wockhardt confirmed the news and said the recall would result in a one-time charge of 1.5 million pounds ($2.25 million) this year. Exports from the Waluj plant constitute less than 5% of the company's total U.K. sales and less than 2% of overall sales, it added.

It was the second recent setback for the company and its Waluj factory. In May, the U.S. Food and Drug Administration imposed an import ban on products from the factory after it failed an FDA safety inspection. The FDA didn't elaborate on the problems it found.

In a conference call at the time, Wockhardt Chairman Habil Khorakiwala said the company was implementing "corrective measures to be in compliance with the FDA guidelines." He said the U.S. import ban could cost the company $100 million in revenue this fiscal year. Wockhardt generated total revenue of 25.6 billion rupees ($460.6 million) in the year ended March 31, 2012.

Also in May, India's Ranbaxy Laboratories Ltd. (500359.BY) agreed to pay $500 million in civil and criminal fines for exporting adulterated drugs to the U.S.

In a phone interview Thursday, D.G. Shah, secretary-general of the Indian Pharmaceutical Alliance, an industry body, said the group has written to the FDA asking it to conduct workshops with Indian companies to correct erroneous practices.

"Companies need to better understand FDA processes, and there needs to be a correction in their organizational culture, right from drug discovery to development and production," Mr. Shah said.

Write to Jeanne Whalen at jeanne.whalen@wsj.com and Anirban Chowdhury at anirban.chowdhury@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 11, 2013 13:45 ET (17:45 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
27 May
PNDORA
Normal 0 21 false false false DA X-NONE X-NONE ..
36
22 May
 
Hej IceT : Det er kloge ord, du kommer med her. Jeg trak mig tilbage, da jeg var 53 år. Min arbejdsp..
32
23 May
 
For nogle af mine kunder, laver jeg en kvartals-analyse over, hvordan de Nordiske selskabers indtjen..
25
25 May
PNDORA
Tjah det er altid svaert for en amatoer som mig at vide hvornaar er det rigtige tidspunkt at koebe e..
14
24 May
PNDORA
Nej for det er Breaking news.
12
23 May
 
Man korser sig når man ser hvad nogle mennesker kan finde på og skrive, blot fordi de kan gøre det a..
12
23 May
 
Hold øje med at politikere og andre nu som sædvanligt vil mane os til "at stå sammen" og "ikke lade ..
12
25 May
ZEAL
-Jeg mindes ikke at handlet med en aktie som deler vandene så meget som Zealand Pharma. Jeg har vær..
11
23 May
 
Hellere en nytteløs klovn end en svinsk og ubehagelig klovn som dig. Mage til ubehagelig optræden.
11
22 May
VELO
  Så kan der snart ikke bankes mere pessimisme ind den aktie, kunne forstå hvis ledelsen havde forlæ..
11

P. Schoenfeld Asset Management LLP : Form 8.3 - Booker Group plc

26/05/2017 15:00:03
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: P. Schoenfeld Asset Management LLP (b) Owner or..

Alliance Trust PLC : Net Asset Value(s)

26/05/2017 13:45:51
ALLIANCE TRUST PLC                                    At the close of business on Thursday 25 May 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 733.6p -       including income, 743.3p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding income..

Statement re Notification of Transactions of Directors - GRANT OF SHARE AWARDS

26/05/2017 10:15:05
Intermediate Capital Group plc 25 May 2017 Notification of Transactions of Directors GRANT OF SHARE AWARDS In accordance with the UK Financial Services Authority Disclosure and Transparency Rule 3.1.4, the Company wishes to announce that on 25 May 2017 PLC Equity Awards and Deferred Share Awards under the Intermediate Capital Group Omnibus Plan were granted to the Directors named below over ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Novo Nordisk submits application in the US for including data from the DEVOTE trial in the Tresiba® label

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
28 May 2017 13:26:07
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170517.1 - EUROWEB4 - 2017-05-28 14:26:07 - 2017-05-28 13:26:07 - 1000 - Website: OKAY